Why the study?
How does the in-vivo sensitivity of aPTT reagents to heparin compare to in-vitro sensitivity, and what are the implications for the therapeutic range?
How does the in-vivo sensitivity of aPTT reagents to heparin compare to in-vitro sensitivity, and what are the implications for the therapeutic range?
Highlights the variability in aPTT reagent sensitivity to heparin, emphasizing that a universal 1.5-2.5x therapeutic range is inappropriate for all reagents.
Answers are grounded in this paper and cite their sources.
May require reagent-specific aPTT ranges for heparin; leaves open prospective validation of clinical outcomes.
The in-vivo sensitivity to heparin of activated partial thromboplastin time (aPTT) reagents is different from the in-vitro sensitivity. Equivalent therapeutic ranges for reagents of very different sensitivities may be determined from the regression line of aPTT against whole blood clotting time. The commonly used ratio of 1.5 to 2.5 times the normal control value is appropriate for some reagents, but for the other reagents a higher or lower range is appropriate. A suitable aPTT reagent for heparin control should be sensitive both to a threshold effect of heparin and to increasing dosage. Some reagents discriminate poorly at the threshold level.
No takes yet. Share an insight, caveat, or question.
Bain et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: